ExpressPoints: An Evolving Treatment Paradigm in HER2-Positive Breast Cancer

Download this short slideset of essential highlights from a live presentation on the latest developments in managing HER2-positive breast cancer.
Neelima Denduluri, MD, FASCO
Lee Schwartzberg, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 749 KB
Released: July 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Puma Biotechnology, Inc.
Seattle Genetics

Related Content

Commentary from Dr. Sunil Badve on Ki67 testing for patients with early-stage hormone receptor-positive/HER2-negative breast cancer from the American Society of Clinical Pathology (ASCP) and Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Released: December 28, 2021

Downloadable summary slideset with key data from the 2021 SABCS Symposium from Clinical Care Options (CCO)

Released: December 16, 2021

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2021 Expired: December 14, 2022

In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see

Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: December 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings